Biocon and Mylan launch biosimilar Lantus in USA

1 September 2020
biocon-kiran-big

Biocon Biologics India, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon (BSE: 532523) and Mylan (Nasdaq: MYL) yesterday announced the US launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

News of the launch sent Biocon’s shares up 4.2% to 375., while Mylan stock edged up less than 1% to $16.38.nch saw Biocon’s shares close up 4.2% at 375.00 rupees

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biosimilars